To further our mission, we annually award research grants to institutions and medical professionals whose research focuses on cancers that present the greatest opportunities for a homerun cancer cure.
Note: When clicking the "Submit Grant Application" button below you will be redirected to SnapGrant.com to complete the application process.
The Cure Starts Now has funded $21,325,827 in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 135 grants at over 100 hospitals in 17 countries.
Duke University Hospital – $50,000
Identifying Oncolytic Viral Therapy Resistance Mechanisms in Brain Tumors
Funding of PBTCF 2021: PBTC-059 - $25,000
Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma
International DIPG/DMG Registry And Repository - $1,508,198
Children's Cancer Institute - $99,251
Discovering New Epigenetic Players in DIPG Oncogenesis
Northwestern Memorial Hospital - $110,000
Development of Histone Demethylase Inhibitor Against DIPG
The Hospital for Sick Children - $100,000
Methionne Deptrivation as a Therapeutic Strategy for Diffuse Intrinsic Pontine Glioma
Hunter Medical Research Institute - $145,640
Combatt DMG: Combined Anti-tumor Targeting of Diffuse Midline Gliomas
CONNECT Consortium - $489,801.26
CONNECT (COllaborative Network for NEurooncology Clinical Trials) Consortium
International DIPG/DMG Registry And Repository - $862,671
Funding of PBTCF 2020: PBTC-058 - $25,000
PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Sydney Children's Hospital - $151,468
Developing New Epigenetic Combination Treatments Against DIPG.
University of Sydney - $100,000
Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an approach of radiosensitization for diffuse intrinsic pontine gliomas.
University of Michigan Hospitals - $157,856
Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG